[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603290":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":65,"collaborators":68,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":28,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":28,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":46,"whyStopped":28,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"National University Health System, Singapore","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"C-CAPD therapy","ACTIVE_COMPARATOR","The prescription for the C-CAPD therapy is as follows:\n\n1. PD solution containing 1.5%, 2.5% dextrose (or its equivalent, for example, 2.3%), 4.25%.\n2. Full fill volume computed as 1100-1400 ml\u002Fm2 as described by Fischbach et al. \\[19\\],\n3. Day-time and night-time dwell time ranging from 3 to 6 hours\n4. Two to 3-daytime exchanges with or without night exchange\n5. 8 to 10 hours of overnight dwell",[13,14],"Other: C-CAPD Prescription","Other: M-CAPD Prescription",{"label":16,"type":17,"description":18,"interventionNames":19},"M-CAPD Therapy","EXPERIMENTAL","The prescription for the M-CAPD therapy is the C-CAPD with an additional 1 to 2 short, low-volume, 15 to 30-minute dwells per exchange before instilling the computed full dwell volume.",[13,14],[21,26],{"type":6,"name":22,"description":18,"armGroupLabels":23,"otherNames":24},"C-CAPD Prescription",[9,16],[25],"M-CAPD Prescription",{"type":6,"name":25,"description":18,"armGroupLabels":27,"otherNames":28},[9,16],null,[30],{"name":31,"affiliation":5,"role":32},"Hui Kim Yap, Professor","PRINCIPAL_INVESTIGATOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":28,"email":38},"Sharon Teo, Consultant","CONTACT","+65 91678482","sharon_teo@nuhs.edu.sg",{"name":40,"role":36,"phone":41,"phoneExt":28,"email":42},"Mya Than","+65 67722460","than_mya@nuhs.edu.sg",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Philippine General Hospital","RECRUITING","Manila","Ermita","1000 Metro Manila","Philippines","PH",{"type":53,"coordinates":54},"Point",[55,56],120.9822,14.6042,{"lat":56,"lon":55},[59,63],{"name":60,"role":36,"phone":61,"phoneExt":28,"email":62},"Lourdes Paula R. Resontoc, MD","+63 9178309796","lrresontoc@up.edu.ph",{"name":64,"role":32,"phone":28,"phoneExt":28,"email":28},"Lourdes Paula R. Resontoc, MG",{"type":32,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Sharon Teo","Consultant",[69,71,74,77],{"name":70,"class":6},"University of the Philippines Manila - Philippine General Hospital",{"name":72,"class":73},"Hospital Tuanku Jaafar, Seremban, Negeri Sembilan","UNKNOWN",{"name":75,"class":76},"Dr. Soetomo General Hospital","OTHER_GOV",{"name":78,"class":73},"Pediatric Institute, Hospital Kuala Lumpur","100603290","comparing-conventional-continuous-ambulatory-peritoneal-dialysis-prescription-c-capd-with-modified-capd-m-capd-prescription-in-children-with-end-stage-kidney-disease-from-low-resource-settings-100603290",false,"NCT07134595","Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Prescription in Children With End-stage Kidney Disease From Low-resource Settings","A Multicenter Study Comparing Conventional Continuous Ambulatory Peritoneal Dialysis Prescription (C-CAPD) With Modified-CAPD (M-CAPD) Prescription in Delivering High Quality Goal-directed Peritoneal Dialysis in Children With End-stage Kidney Disease From Low-resource Settings: MaxED-OUT Trial","Inclusion Criteria:\n\n* CKD 5D who have been on peritoneal dialysis for at least three months.\n\nExclusion Criteria:\n\n1. Patients with BSA of ≥1.5 m2,\n2. Evidence of mechanical causes of low ultrafiltration capacity (hernia, peri-catheter, or genital leaks, pleuroperitoneal communication),\n3. Peritoneal membrane failure (encapsulating peritoneal sclerosis),\n4. Recent episode of peritonitis (within two months)\n5. Those who have been on hemodialysis before switching to PD in the last three weeks.","ALL","2 Years","18 Years",{"count":90,"type":91},44,"ESTIMATED","INTERVENTIONAL",[94],"NA","This study aims to compare modified CAPD (M-CAPD) and conventional CAPD (C-CAPD) in terms of delivering high-quality, goal-directed PD as well as avoiding resource wastage in prevalent ESKD patients aged 2 to ≤18 years using a randomized cross-over study design for one year.\n\nThis study hypothesizes that M-CAPD will have better ultrafiltration and solute clearance than C-CAPD.\n\nSpecific objectives\n\n1. To determine the ultrafiltration efficiency by measuring the following:\n\n   1. Clinical parameters: blood pressure, weight, evidence of fluid overload by the presence of edema, abnormal heart sounds (S3 gallop), lung crackles or rales, increased heart rate (tachycardia), rapid breathing (tachypnea),\n   2. Change in the number of blood pressure medications before and after the intervention,\n   3. Absolute and relative fluid overload using bioimpedance analyzer (BIA),\n   4. Mean daily ultrafiltration (UF) or Total 24-h UF,\n   5. Residual kidney function: 24-hour urine output,\n   6. Glucose exposure\n2. To determine the solute clearance adequacy by measuring the following:\n\n   1. Serum sodium, chloride, potassium, bicarbonate, serum albumin, calcium, and hemoglobin,\n   2. Phosphate clearance\n   3. Renal and peritoneal Kt\u002FVurea\n   4. Normalized protein catabolic rate (nPCR)\n3. To measure caregiver burden using a Paediatric Renal Caregiver Burden Scale (PR-CBS).",[97],"Children on Chronic Peritoneal Dialysis",[99,100,101,102,103],"M-CAPD","C-CAPD","ESKD","Children","Low-resource settings","2025-08-19",{"date":106,"type":107},"2025-08-21","ACTUAL",{"date":109,"type":107},"2024-11-18",{"date":111,"type":91},"2026-06-30",{"name":5,"class":6},1]